Medication Discontinuation: Potential Causes and Consequences

Stopping a prescribed medication is one of the most common events in healthcare, and it happens for a tangled mix of reasons ranging from intolerable side effects to an inability to afford refills. The consequences vary just as widely: sometimes nothing happens, sometimes symptoms return worse than before, and sometimes the abrupt absence of a drug triggers an entirely new medical problem. What makes medication discontinuation tricky to talk about in general terms is that it can be a dangerous lapse, a rational personal decision, or a carefully supervised clinical strategy, depending entirely on the drug, the disease, and the circumstances.

Side Effects Push People Out Early

Adverse effects are the most intuitive reason people stop a medication, and the data back that up. In a survey of nearly 4,000 patients who had recently started a new drug, about one in six of those who experienced side effects had already stopped the medication by the time the survey reached them, and the majority of those discontinuations happened within the first month.¹ That finding alone would seem straightforward: people feel bad, people stop. But the same study found that the decision to quit was heavily shaped by factors beyond the physical discomfort itself, including how well the prescriber communicated about what to expect and whether the patient believed the drug was necessary.

Which side effects actually drive people to quit can also be surprising. A large retrospective study of more than 20,000 antidepressant users found that the two most commonly reported side effects, reduced sexual function and weight gain, were not associated with higher odds of discontinuation. Instead, it was symptoms like anxiety, agitation, suicidal thoughts, vomiting, and rashes that predicted stopping treatment.² The implication is that tolerability is not just about severity; it is about whether a side effect feels alarming or destabilizing versus merely annoying.

The Cost Problem

Financial strain is a quieter but pervasive driver of discontinuation, especially in the United States. Among adults 65 and older, roughly one in five reported skipping doses, delaying refills, or stopping medications altogether because of cost.³ That number climbs sharply in younger disabled populations on Medicare: about a third of enrollees under 65 with a disability reported not taking medications as prescribed due to high costs, and nearly one in five went without other essentials like food or utilities to pay for their drugs.⁴

Income matters, but not in a perfectly linear way. Medicare beneficiaries with incomes just above the threshold for low-income subsidies had about 50% higher odds of cost-related nonadherence compared with those earning more, while the very poorest beneficiaries, who were more likely to qualify for subsidies, did not have significantly higher risk.⁴ People stuck in the gap between qualifying for help and being able to afford their drugs on their own are the most vulnerable. Some turn to alternative therapies as a cheaper substitute: an estimated 12.3 million American adults used complementary or alternative medicine specifically to save money on prescriptions, with uninsured adults doing so at roughly double the rate of the general population.⁵

Why Beliefs Matter as Much as Biology

Whether someone sticks with a medication has as much to do with what they believe about it as with what the drug is actually doing in their body. A meta-analysis spanning 94 studies found that people who perceived their medication as necessary were significantly more likely to take it as prescribed, while those with stronger concerns about the drug, such as fear of dependence or long-term harm, were roughly half as likely to adhere.⁶ A systematic review of health-psychology models applied to adherence found that self-efficacy, a person’s confidence in their own ability to follow a treatment plan, was the single most consistent predictor across studies.⁷

These beliefs do not form in a vacuum. In heart patients, those who stopped cholesterol-lowering therapy were more likely to believe they simply did not need it compared with patients who stopped antiplatelet drugs, suggesting that the perceived seriousness of the condition shapes the willingness to keep going.⁸ And there is a meaningful difference between someone who decides to stop after weighing their options and someone who simply forgets or loses track. Intentional nonadherence is consistently linked to dissatisfaction with treatment, including the quality of the relationship with medical staff, while unintentional nonadherence, the kind driven by forgetfulness or confusion, operates through different channels entirely.⁹

How Media Coverage and the Nocebo Effect Fuel Discontinuation

Sometimes the trigger for stopping a medication comes from outside the clinic altogether. The nocebo effect, where negative expectations produce real symptoms, can be amplified by media coverage in dramatic fashion. After British media highlighted concerns about statin side effects in 2013, an estimated 200,000 patients stopped taking statins within six months, many citing adverse reactions that researchers later attributed largely to the nocebo effect rather than the drug’s pharmacology.¹⁰ The nocebo response can be triggered by verbal suggestions from a clinician, by reading frightening information in a package insert, or by watching other patients report negative experiences.¹⁰

This creates a genuinely difficult situation for clinicians. Informed consent demands that patients know about potential side effects, but the act of describing those side effects can itself increase the likelihood that patients experience them and then stop treatment. The problem extends to newer drug categories like biosimilars, where patients switched from an originator biologic to a cheaper copy sometimes report worse outcomes driven by expectation rather than any difference in the drug itself.¹¹

Complexity, Shortages, and System-Level Causes

Older adults managing several chronic conditions at once face a compounding challenge: the more medications on the list, the harder it gets to keep track of them all. Polypharmacy, taking five or more drugs daily, is a well-documented risk factor for nonadherence in older populations.¹² The confusion is not just about remembering when to take what. Complex regimens with different dosing schedules, dietary restrictions, and conflicting instructions create opportunities for error at every step.

Drug shortages add another layer. When a commonly used blood pressure medication, valsartan, was recalled due to contamination concerns, nearly 70% of users discontinued it, though most switched to alternative treatments rather than going without blood pressure medication entirely.¹³ Not every shortage resolves so smoothly. A scoping review of medication shortages found that forced treatment interruptions can cause genuine harm: in one example, HIV patients whose antiretroviral therapy was interrupted due to supply problems developed more drug-resistance mutations and had worse viral control than those whose treatment continued uninterrupted.¹⁴

What Happens to the Body After Abrupt Discontinuation

When a drug has been altering the body’s chemistry for weeks or months, the body adjusts. Remove the drug suddenly, and those adjustments are left unopposed. The result can be a rebound effect, where the original symptom returns more intensely than before, or a full withdrawal syndrome with symptoms that never existed prior to treatment. Rebound hypertension after suddenly stopping blood pressure drugs is a classic example, where blood pressure may spike to levels higher than the original baseline.¹⁵

In psychiatry and neurology, withdrawal syndromes can be particularly disorienting. Abruptly stopping certain medications can produce seizures and delirium, which are qualitatively different from the condition being treated and can be life-threatening.¹⁶ Antidepressant discontinuation syndrome, seen with SSRIs, involves a cluster of symptoms including dizziness, sensory disturbances sometimes described as “brain zaps,” gastrointestinal upset, sleep disruption, and anxiety, none of which need to have been present before the medication was started.¹⁷ These symptoms typically begin within days of stopping and can last weeks if not managed with a gradual taper.

Stopping Statins After a Stroke or Heart Event

Statins offer one of the clearest case studies in the consequences of discontinuation. In patients who had already experienced a stroke, those who stopped their statins had a recurrent stroke rate of about 6.2% within a year, compared with 4.4% for those who continued, and all-cause mortality was also significantly higher in the group that stopped.¹⁸ An earlier review found that abrupt statin discontinuation produces a shift toward a more inflammatory, clot-prone state, and that this effect matters most during an acute event: stopping statins during acute coronary syndrome significantly increased illness and death, while stopping during stable periods appeared safer.¹⁹

Even in people taking statins for prevention rather than after an event, stopping carries measurable risk. A Danish study found that older adults who discontinued statin therapy experienced roughly 9 additional major cardiovascular events per 1,000 person-years in the primary prevention group and 13 additional events per 1,000 person-years in the secondary prevention group, compared with those who stayed on treatment.²⁰ The risk was not enormous for any individual person, but across populations, those numbers add up.

Psychiatric Relapse After Stopping Antipsychotics

For people with psychotic disorders, the stakes of stopping medication tend to be high. A meta-analysis of first-episode psychosis patients found that those who discontinued antipsychotics had a relapse rate of about 53% at 12 months, compared with 21% for those who stayed on treatment.²¹ The gap between the two groups appeared within just a couple of months and remained stable through two years of follow-up.

Degree of recovery before stopping matters considerably. Among people with schizophrenia spectrum disorders who attempted discontinuation, those who had achieved a full recovery beforehand had a one-year relapse rate around 37%, while those who had only partially recovered relapsed at 65%. By three years, the partially recovered group reached 85%.²² The honest clinical picture is that stopping antipsychotics is risky even under the best circumstances, and the risk rises sharply if the person was not fully stable to begin with. This does not mean discontinuation should never be attempted, but it underlines why it should be done under close supervision with a clear plan for monitoring.

When Stopping a Medication Is the Right Move

Not all discontinuation is a problem. Deprescribing, the deliberate, supervised reduction or removal of medications that are no longer appropriate, is an increasingly important part of geriatric care. Structured deprescribing protocols use stepwise reviews to identify drugs that may be doing more harm than good, especially in frail older adults on complex regimens.²³ A systematic review of deprescribing in frail older people found that the interventions consistently reduced the number of inappropriate medications per patient, and three studies that tracked safety found no significant increases in adverse events, hospitalizations, or deaths.²⁴

The fear that removing even one drug will cause something terrible tends to be greater than the actual risk. A trial comparing deprescribing of blood pressure drugs in older adults with usual care found no significant differences in death, cardiovascular events, hospitalizations, strokes, heart attacks, or falls between the two groups.²⁵ Separately, a study tracking older adults after hospital-based deprescribing found no higher risk of emergency department visits, readmissions, or death in the 90 days following discharge compared with a control group.²⁶ The evidence does not mean deprescribing is always safe or that any medication can be casually dropped. It means that when a medication has outlived its usefulness or when its risks outweigh its benefits, a supervised withdrawal generally does not create the cascade of problems that patients and clinicians sometimes fear.

The Hospital Transition Gap

One of the most common and preventable causes of unintentional discontinuation is the transition between settings, particularly hospital admission and discharge. When a patient’s medication list at home does not match the list that gets entered into the hospital system, drugs can be inadvertently omitted, duplicated, or given at the wrong dose. A study analyzing reconciliation errors at a large hospital found that at least one error was present in about 65% of patients at admission, with an average of more than two errors per patient. At discharge, about a third of patients had at least one error, and roughly half of those discharge errors had the potential to cause moderate or severe harm.²⁷ The most frequent type of error in both directions was drug omission: a medication the patient was supposed to be taking simply vanished from the list.

This is not a matter of one careless hospital. Medication reconciliation errors are a system-wide problem that persists despite decades of quality-improvement efforts. The risk is highest for patients taking many medications, transferring between multiple care teams, or experiencing cognitive decline that limits their ability to speak up about what they are supposed to be on. If you or a family member are being admitted to or discharged from a hospital, bringing a complete, written medication list, including doses and schedules, remains one of the most practical things you can do to prevent an accidental discontinuation.

The Practical Limits of Tapering

Even when everyone agrees that a medication should be stopped, actually doing so can be mechanically difficult. Many psychiatric drugs require extremely gradual dose reductions, especially in the final stages, where the smallest available tablet may still represent too large a step down. Clinicians face a constant challenge in obtaining flexible doses for the later phases of discontinuation, when lower and lower amounts are needed and commercially available formulations simply do not go that small.²⁸ Patients sometimes resort to splitting tablets, using liquid formulations that were designed for children, or opening capsules and counting beads, all workarounds with obvious precision problems.

This manufacturing gap matters because the relationship between dose reduction and receptor occupancy is not linear for many drugs. Cutting a dose in half does not necessarily reduce the drug’s effect by half. For some medications, particularly SSRIs and antipsychotics, the last stretch of tapering, from a low dose to zero, involves the steepest drop in receptor occupancy and therefore the greatest risk of withdrawal symptoms. Hyperbolic tapering schedules, where dose reductions get progressively smaller as the total dose decreases, are gaining traction in clinical guidance but remain difficult to execute when drugmakers do not produce the needed pill sizes. Until pharmaceutical manufacturing catches up, this practical bottleneck will continue to make safe discontinuation harder than it should be.

Digital Tools and the Adherence Puzzle

Given the scale of the problem, it is worth asking whether technology can help keep people on their medications. Smartphone apps, automated text reminders, electronic pill organizers, and other digital health interventions have been widely promoted as solutions. A recent systematic review and meta-analysis, however, found no statistically significant effect of these digital tools on medication adherence, even when subgroups were analyzed separately.²⁹ That result might seem puzzling, but it makes more sense in light of why people actually stop their medications. A reminder app addresses forgetfulness, which is real but only one slice of the problem. It does nothing for the person who cannot afford the refill, who is frightened by a side effect, who has decided they do not need the drug, or who read a scary news story and lost confidence in the treatment. The causes of discontinuation are deeply varied, and no single intervention can address all of them. What seems to matter most is a trusting relationship with a prescriber who explains what to expect, asks about barriers, and treats the decision to take or stop a drug as something worth discussing rather than assuming.